Please assess the completion status of the following clinical trial:

Trial Title: Systematic Evaluation of Antiviral Medication in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both genders between the ages of 18-50 years~* Schizophrenia or schizoaffective disorder as defined in DSM-IV~* Duration of illness 10 years or less~* On a stable dose of an antipsychotic medication for at least a month~* Should score 4 or more on at least one of the subscales of PANSS~* Positive for HSV1~* Written informed consent~Exclusion Criteria:~* Substance abuse in the last month/dependence 6 months prior to the study~* History of, or current medical/neurological illnesses which affects CNS function e.g., epilepsy, head injury with prolonged loss of consciousness~* Pregnancy~* History of immune disorders, HIV infection or currently receiving immunosuppressants~* Subjects on regular antiviral therapy~* History of hypersensitivity to Valacyclovir~* Mental retardation as defined in DSM-IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Valacyclovir (Type: EXPERIMENTAL): 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): 2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).